
## Sabina Frljak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8948267/publications.pdf Version: 2024-02-01



SARINA FRIJAK

#	Article	IF	CITATIONS
1	Transendocardial CD34 <sup>+</sup> Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy. Cell Transplantation, 2022, 31, 096368972210803.	2.5	2
2	Cell Therapy in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 2022, 8, e08.	3.0	3
3	Effects of sacubitril/valsartan in patients with left ventricular assist devices: Case series. Artificial Organs, 2021, 45, 185-186.	1.9	1
4	Abstract 12017: Correlates of Regional Diastolic Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. Circulation, 2021, 144, .	1.6	0
5	Larger End-Diastolic Volume Associates With Response to Cell Therapy in Patients With Nonischemic Dilated Cardiomyopathy. Mayo Clinic Proceedings, 2020, 95, 2125-2133.	3.0	7
6	Stem Cell Therapy for Chronic and Advanced Heart Failure. Current Heart Failure Reports, 2020, 17, 261-270.	3.3	3
7	Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction. Diagnostics, 2020, 10, 522.	2.6	4
8	Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review. Biomedicines, 2020, 8, 570.	3.2	11
9	Response to the letter to the editor: unravel the genetic background of noncompaction before relating it with myocardial hypoperfusion. ESC Heart Failure, 2020, 7, 1999-2000.	3.1	1
10	Impairment of myocardial perfusion correlates with heart failure severity in patients with nonâ€compaction cardiomyopathy. ESC Heart Failure, 2020, 7, 1161-1167.	3.1	5
11	QuantiFERON-CMV guided virostatic prophylaxis after heart transplantation. Journal of Heart and Lung Transplantation, 2020, 39, 278-281.	0.6	10
12	Abstract 15652: Cell Therapy in Heart Failure With Preserved Ejection Fraction (CELLpEF). Circulation, 2020, 142, .	1.6	1
13	Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure. Cell Transplantation, 2019, 28, 856-863.	2.5	2
14	Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. Disease Markers, 2019, 2019, 1-8.	1.3	1
15	CD34+ Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy. Stem Cells Translational Medicine, 2018, 7, 168-172.	3.3	15
16	Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure. Stem Cells International, 2018, 2018, 1-8.	2.5	10
17	Transendocardial CD34 <sup>+</sup> Cell Transplantation in Noncompaction Cardiomyopathy. Cell Transplantation, 2018, 27, 1027-1030.	2.5	3
18	Effects of Repetitive Transendocardial CD34 <sup>+</sup> Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy. Circulation Research, 2018, 123, 389-396.	4.5	25

SABINA FRLJAK

#	Article	IF	CITATIONS
19	Effects of Transendocardial CD34+ Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated Cardiomyopathy. Stem Cells Translational Medicine, 2017, 6, 1515-1521.	3.3	17
20	Electroanatomic Properties of the Myocardium Predict Response to CD34+ Cell Therapy in Patients With Ischemic and Nonischemic Heart Failure. Journal of Cardiac Failure, 2017, 23, 153-160.	1.7	11
21	Successful heart transplantation in an adult patient with partial anomalous pulmonary venous return from the left upper lobe. International Journal of Cardiology, 2015, 186, 106-108.	1.7	2
22	Estimating the Universal Positions of Wireless Body Electrodes for Measuring Cardiac Electrical Activity. IEEE Transactions on Biomedical Engineering, 2013, 60, 3368-3374.	4.2	31
23	Effect of cardiac resynchronization therapy on beat-to-beat T-wave amplitude variability. Europace, 2012, 14, 1646-1652.	1.7	9